Weekly subcutaneous pegylated recombinant native human leptin (PEG-OB) administration in obese men

Journal of Clinical Endocrinology and Metabolism

Volumn 85, Issue 11, 2000, Pages 4003-4009

  Hukshorn, Chris J ^a   Saris, Wim H M ^a   Westerterp Plantenga, Margriet S ^a   Farid, Adrienne R ^b   Smith, Francoise J ^c   Campfield, L Arthur ^c  

^a MAASTRICHT UNIVERSITY   (Netherlands)

^b HOFFMANN LA ROCHE INC   (United States)

^c Department of Environmental and Radiological Health Sciences   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LEPTIN; PEGYLATED RECOMBINANT NATIVE HUMAN LEPTIN; PLACEBO; RECOMBINANT PROTEIN; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BODY COMPOSITION; BODY FAT; BODY MASS; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION FUNCTION; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG TOLERABILITY; ENERGY EXPENDITURE; HUMAN; LOW CALORY DIET; MALE; OBESITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY QUOTIENT; SIDE EFFECT; WEIGHT REDUCTION;

EID: 0034522997     PISSN: 0021972X     EISSN: None     Source Type: Journal    
DOI: 10.1210/jcem.85.11.6955     Document Type: Article

References (34)

1. Environmental contributions to the obesity epidemic
2. Strategies and potential molecular targets for obesity treatment
3. Overview: Neurobiology of OB protein (leptin)
4. OB protein: A hormonal controller of central neural networks mediating behavioral, metabolic and neuroendocrine responses
5. Serum immunoreactive-leptin concentrations in normal-weight and obese humans
6. Leptin levels in human and rodent: Measurement of plasma leptin and ob mRNA in obese and weight-reduced subjects
7. Recombinant leptin for weight loss in obese and lean adults
8. Effects of recombinant leptin therapy in a child with congenital leptin deficiency
9. Pharmacokinetics of recombinant human leptin in mice
10. Pharmacokinetics of recombinant leptin in rats
11. Pharmacokinetics of recombinant human methionyl human leptin (rL) and the effect of antibody formation in lean and obese subjects following subcutaneous (sc) dosing
12. The clinical efficacy of poly(ethylene glycol)modified proteins
13. A phase I study including pharmacokinetics of polyethylene glycol conjugated interleukin-2
14. The therapeutic value of poly(ethylene glycol)-modified proteins
15. Chronic administration of OB protein decreases food intake by selectively reducing meal size in female rats
16. Chronic administration of OB protein decreases food intake by selectively reducing meal size in male rats
17. Changes in nutrient oxidation in response to a high-fat diet
18. A dual respiration chamber with automated calibration
19. New methods for calculating metabolic rate with special reference to protein metabolism
20. The Maastricht protocol for the measurement of body composition and energy expenditure with labeled water
21. Body composition from fluid spaces and density: Analysis of methods
22. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of preparative ultra centrifuge
23. Estimates of in vivo insulin action in man: Comparison of insulin tolerance tests with euglycemic and hyperglycemic glucose clamp studies
24. Weight control and risk factor reduction in obese subjects treated for two years with orlistat
25. Randomised placebocontrolled trial of orlistat for weight loss and prevention of weight regain in obese patients
26. Role of orlistat in the treatment of obese patients with type 2 diabetes
27. Efficacy of exogenous recombinant murine leptin in lean and obese 10-to 12-mo-old female CD-1 mice
28. Regulation of fatty acid homeostasis in cells; novel role of Leptin
29. Changes in appetite following weekly PEG-OB protein administration during an energy restricted diet in obese men